visitante ::
identificación
|
|||||||||||||||
Buscar | Enviar | Ayuda | Servicio de Bibliotecas | Sobre el DDD | Català English Español |
Página principal > Artículos > Artículos publicados > Early pseudoprogression and progression lesions in glioblastoma patients are both metabolically heterogeneous |
Fecha: | 2024 |
Resumen: | The standard treatment in glioblastoma includes maximal safe resection followed by concomitant radiotherapy plus chemotherapy and adjuvant temozolomide. The first follow-up study to evaluate treatment response is performed 1 month after concomitant treatment, when contrast-enhancing regions may appear that can correspond to true progression or pseudoprogression. We retrospectively evaluated 31 consecutive patients at the first follow-up after concomitant treatment to check whether the metabolic pattern assessed with multivoxel MRS was predictive of treatment response 2 months later. We extracted the underlying metabolic patterns of the contrast-enhancing regions with a blind-source separation method and mapped them over the reference images. Pattern heterogeneity was calculated using entropy, and association between patterns and outcomes was measured with Cramér's V. We identified three distinct metabolic patterns-proliferative, necrotic, and responsive, which were associated with status 2 months later. Individually, 70% of the patients showed metabolically heterogeneous patterns in the contrast-enhancing regions. Metabolic heterogeneity was not related to the regions' size and only stable patients were less heterogeneous than the rest. Contrast-enhancing regions are also metabolically heterogeneous 1 month after concomitant treatment. This could explain the reported difficulty in finding robust pseudoprogression biomarkers. |
Ayudas: | European Commission 813120 Instituto de Salud Carlos III PI20/00064 Instituto de Salud Carlos III PI20/00360 Ministerio de Economía y Competitividad SAF2014-52332-R Ministerio de Sanidad y Consumo CB06/01/0010 Agencia Estatal de Investigación PID2019-104551RB-I00 Agència de Gestió d'Ajuts Universitaris i de Recerca 2018/XARDI-00016 Agència de Gestió d'Ajuts Universitaris i de Recerca 2021/XARDI-00021 |
Nota: | Altres ajuts: acords transformatius de la UAB |
Derechos: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades. |
Lengua: | Anglès |
Documento: | Article ; recerca ; Versió publicada |
Publicado en: | NMR in Biomedicine, (January 2024) , Art. e5095, ISSN 1099-1492 |
Obra relacionada: | Ungan, Gulnur; Pons-Escoda, Albert; Ulinic, Daniel; Arús i Caraltó, Carles; Ortega-Martorell, Sandra; Olier, Ivan; Vellido, Alfredo; Majós, Carles; Julià Sapé, Margarida, 2026, Replication data for "Early pseudoprogression and progression lesions in glioblastoma patients are both metabolically heterogeneous", CORA.Repositori de Dades de Recerca, V1 https://doi.org/10.34810/data1018 |
12 p, 2.7 MB |
Supplementary material 16 p, 2.3 MB |